[Congressional Record Volume 171, Number 131 (Wednesday, July 30, 2025)]
[Senate]
[Pages S4923-S4924]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  SA 3144. Mr. BUDD (for himself and Mr. Heinrich) submitted an 
amendment intended to be proposed by him to the bill H.R. 3944, making 
appropriations for military construction, the Department of Veterans 
Affairs, and related agencies for the fiscal year ending September 30, 
2026, and for other purposes; which was ordered to lie on the table; as 
follows:

       At the appropriate place in division B, insert the 
     following:

[[Page S4924]]

       Sec. __.  The Food and Drug Administration shall utilize 
     existing regulatory and enforcement authorities to prevent 
     the importation of GLP-1 and GIP/GLP-1 drugs that appear to 
     be counterfeit, unapproved, misbranded, or adulterated from 
     the Republic of China or other foreign countries, including 
     any bulk drug substance or active pharmaceutical ingredient 
     from facilities in China. Such regulatory and enforcement 
     authorities include issuing warning letters, initiating civil 
     enforcement actions, and refusing the entry of drugs, 
     including bulk drug substances, and active pharmaceutical 
     ingredients used in drugs from such facilities.
                                 ______